Longitudinal Analysis of 1α,25-dihidroxyvitamin D and Homocysteine Changes in Colorectal Cancer
Overview
Authors
Affiliations
Background: 1α,25-dihydroxycholecalciferol (1,25(OH)D) and homocysteine are known to play a role in the pathophysiology of colorectal cancer (CRC). In health, the two changes are inversely proportional to each other, but little is known about their combined effect in CRC.
Methods: The serum 1,25(OH)D and the homocysteine levels of eighty-six CRC patients were measured, who were enrolled into four cohorts based on the presence of metastases (Adj vs. Met) and vitamin D supplementation (ND vs. D).
Results: 1,25(OH)D was constant (Adj-ND), increased significantly (Adj-D, = 0.0261), decreased (Met-ND), or returned close to the baseline after an initial increase (Met-D). The longitudinal increase in 1,25(OH)D (HR: 0.9130, = 0.0111) positively affected the overall survival in non-metastatic CRC, however, this effect was cancelled out in those with metastasis ( = 0.0107). The increase in homocysteine negatively affected both the overall (HR: 1.0940, = 0.0067) and the progression-free survival (HR: 1.0845, = 0.0073). Lower 1,25(OH)D and/or higher homocysteine level was characteristic for patients with higher serum lipids, albumin, total protein, white blood cell and platelet count, male sex, and right-sided tumors. No statistically justifiable connection was found between the target variables.
Conclusions: A measurement-based titration of vitamin D supplementation and better management of comorbidities are recommended for CRC.